Jagsonpal Pharmaceuticals Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/dzbve8srfcrwijqoann5el4h.pdf

Key Takeaways


The Dydrogesterone Reset

Manish Gupta: "Both the competitive intensity and wherein there was a lot of push and as I said, there was very little pull element, we took a backseat as far as this molecule is concerned and it has dropped by almost 75% for us."

Yash Pharma Integration & Portfolio Shift


Organic Growth: The Core Challenge

Manish Gupta: "Are we growing? Answer is yes. Are we growing as much as we would like to? The answer is no."

Margins & Working Capital

Manish Gupta: "Earlier we never paid our creditors or vendors on time. But for last 18 months, every vendor is paid on the due date, which is a principle that we have adopted in our company."

Capital Allocation & M&A

Manish Gupta: "Unless we can find something which adds value to our shareholders, it is better to return it rather than doing any acquisition for pride."

Pricing & Competitive Positioning


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth15%+ (all organic except small Yash Pharma month-count tailwind)FY26
Revenue growth12–14% with 100–150 bps margin improvement year-on-yearBeyond FY26
New product launches4–6 annually, roughly half brand extensions and half new conceptsOngoing
MR productivityMove PCPM from ~₹2–2.1 lakhs to ₹3–3.5 lakhsNext 3–4 years
Working capitalNo further material reduction expected below ~3% of salesOngoing
Capital allocationReturn cash to shareholders if no value-accretive acquisition foundNo fixed timeline

Key Metrics

MetricQ4 FY25
Revenue₹58.6 cr, +34.7% YoY
Full-year revenue₹268.7 cr, +28.8% YoY
Operating EBITDA₹9.7 cr, +97% YoY
Operating EBITDA margin15.6%, +530 bps YoY
Full-year operating EBITDA₹57.9 cr, +59% YoY
PAT₹6.6 cr, +88.5% YoY
PAT margin11.2%, vs 8.2% last year
Full-year PAT₹55.4 cr, vs ₹22.5 cr last year
Full-year PAT margin20.6%, +320 bps YoY
Operating PAT (adjusted for exceptional items)₹37.5 cr (full year)
Cash balance₹145 cr
Organic revenue growth8% (full year); 1% in H1, 15% in H2
Working capital3.5% of sales (13 days)
Medical rep field force~1,000 reps
PCPM (per capita per month)₹2 to ₹2.1 lakh
Gross margin~65%
FY26 revenue growth guidance15%+
Beyond FY26 revenue growth guidance12%–14%, with 100–150 bps margin improvement YoY